A pooled analysis of six clinical trials involving 573 patients with high-risk resectable melanoma compared the safety and efficacy of neoadjuvant combination therapy with anti-PD-1 and anti-CTLA-4 inhibitors to anti-PD-1 monotherapy. This evidence concerns the gene CTLA4 and melanoma.